Eli Lilly: A Safe Harbor Amid Market Volatility
Eli Lilly's stock is undervalued; defensive healthcare stocks shine amid uncertainty, and Eli Lilly drives growth. Click here ...
FDA voices ‘concerns’ with unapproved GLP-1 drugs used for weight loss
FDA is aware that some patients and health care professionals may look to unapproved versions of GLP-1 – glucagon-like peptide-1 receptor agonists – drugs, including semaglutide and tirzepatide, as an ...
Citi sees positive read-through to Lilly shares on FDA GLP-1 statement
Citi reiterated a Buy rating and $1,190 price target on Eli Lilly (LLY), saying the firm expects a positive read-through to the shares on FDA’s ...
Healio11h
Societies take stand against off-brand GLP-1s over safety concerns
A rise in the use of non-FDA-approved diabetes and obesity medications has spurred health care professionals and medical ...
The Manila Times14h
Maxion Therapeutics Raises $72 million (£58 million) in an Oversubscribed Series A Financing to Advance its KnotBody® Pipeline and Platform
This oversubscribed Series A funding round was led by General Catalyst with additional investment from new investors, British ...
3 Unstoppable Stocks You Can Buy Now Without Any Hesitation
Are you reluctant to invest in stocks right now? That's understandable. Fear, uncertainty, and doubt have become the norm in ...
The weight loss drug shortage is over — and some patients are 'panicking'
In this photo illustration, boxes of the diabetes drug Ozempic rest on a pharmacy counter on April 17, 2023 in Los Angeles, California.For Maria Rising, managing her health felt like chasing a phantom ...
Drug developers ‘haven’t even scratched the surface’ of what radiopharma can do
Even with Big Pharmas pouring billions into the space, the potential of radiopharmaceuticals remains largely untapped.